Eli Lilly has extended eligibility for its UK LillyDirect dispensing and delivery scheme, launched in June 2026 with Pharmacy2U and BlueCo Healthcare's Onescript as exclusive dispensing partners, to any GPhC- or PSNI-regulated pharmacy running a private weight management service; this is a distribution expansion, not a transaction, and no deal consideration arises.

Eli Lilly is an Indianapolis-based pharmaceutical company (NYSE: LLY), the world's largest by market capitalisation. Mounjaro and Zepbound combined generated $36.5 billion in sales in 2025, making tirzepatide the world's best-selling medicine, overtaking Merck's Keytruda. UK-specific Mounjaro revenues are not separately disclosed.

Pharmacy2U is the UK's largest online NHS pharmacy; Onescript is BlueCo Healthcare's private dispensing arm; neither discloses LillyDirect-specific revenue. Advisors: none mentioned.

The structural driver is counterfeit supply chain risk. LillyDirect is explicitly positioned as an anti-falsification mechanism: by routing private Mounjaro prescriptions through GPhC-regulated dispensing partners to patients in verified cold-chain packaging, Lilly creates a traceable, manufacturer-endorsed supply route that the unregulated online GLP-1 market cannot replicate.

The UK's MHRA reported a 400% increase in seized fake weight-loss injection products between 2023 and 2025. The original June launch restricted eligibility to non-pharmacy clinics, creating an anomaly where GPhC-regulated pharmacies were excluded from a scheme they were structurally best placed to operate. The extension corrects that directly.

The commercial logic for Lilly is clear: expanding the eligible prescriber base increases the volume of private Mounjaro routed through a manufacturer-controlled channel, reducing counterfeit displacement risk to its revenue and building UK patient relationship infrastructure ahead of the anticipated NHS rollout under NICE TA1026, being phased from specialist services to primary care through 2027.

For Ireland, LillyDirect does not currently operate under the Health Products Regulatory Authority framework, but the GPhC eligibility model is being watched closely by Irish pharmacists and prescribers as a potential template for authenticated dispensing in the Republic if Lilly extends the scheme.

Source: pharmacymagazine.co.uk / pharmaphorum.com / biopharmadive.com / nice.org.uk / pharmacy.biz